Idenix HCV drug on hold; stock falls 25.7%
This article was originally published in Scrip
Executive Summary
Idenix Pharmaceuticals fell 25.7% in after-hours trading to $3.81 per share on 20 June based on the delayed start of clinical studies for the company's lead uridine nucleotide prodrug candidate IDX20963 following the US FDA's request for more preclinical safety data for the prospective hepatitis C virus (HCV) drug.